Lifeloc Narrows Q3 Loss on 12% Revenue Growth, But Pushes SpinDetect Launch to Q4 2027
LCTC has more than doubled off its 52-week low of $1.75 on light trading volume (0.1× avg).
Summary
Lifeloc posted Q3 2026 revenue of $2.522 million, up 12% from $2.257 million a year earlier, and cut its net loss to $84,931 ($0.03 per diluted share) from $263,439 ($0.10). Gross margin improved to 43% from 40% on price increases and a better product mix, and the nine-month loss shrank to $372 thousand from $950 thousand. The offsetting item is SpinDetect: the limited commercial launch of the centrifugal drug analyzer slips from Q1 2027 to Q4 2027, with management redirecting some engineering resources back to core breath-alcohol products to generate near-term cash. R&D stayed elevated at $506 thousand for the quarter, and the balance sheet shows $930,539 of cash plus a $500,000 related-party term loan drawn during the nine months. For a company this small, the delay matters more than the modest revenue beat — the growth story now depends on core product upgrades funding SpinDetect development.
At the time of this announcement, LCTC was trading at $3.50 on OTC in the Manufacturing sector, with a market capitalization of approximately $9.6M. The 52-week trading range was $1.75 to $5.58. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: ACCESS Newswire.